Annual report pursuant to Section 13 and 15(d)

Notes Payable

v3.22.1
Notes Payable
12 Months Ended
Dec. 31, 2021
Notes Payable  
Notes Payable

Note 8 – Notes Payable

On March 29, 2019 (the “Closing Date”), the Company entered into a $20.0 million Loan Agreement with Horizon, the proceeds of which provided the Company with additional working capital to continue development of its gene and cell therapies. In accordance with the Loan Agreement, $15.0 million of the $20.0 million loan was funded on the Closing Date, with the remaining $5.0 million fundable upon the Company achieving certain predetermined milestones.

Amortization of the debt discount associated with the funded loans was approximately $2.3 million for the year ended December 31, 2020, and was included in interest expense in the Statements of Operations.

On September 30, 2020, the Company repaid the amount outstanding under the Horizon Notes in full, which was comprised of $15.0 million face value of the outstanding notes, $0.1 million in accrued and unpaid interest, a $0.8 million final payment fee and prepayment penalties of $0.6 million. For the year ended December 31, 2020, the Company recorded interest expense of approximately $2.1 million related to the early repayment of the Horizon Notes.